286 related articles for article (PubMed ID: 35388118)
1. The role of JAK inhibitors in hematopoietic cell transplantation.
Salit RB
Bone Marrow Transplant; 2022 Jun; 57(6):857-865. PubMed ID: 35388118
[TBL] [Abstract][Full Text] [Related]
2. Recent progress of JAK inhibitors for hematological disorders.
Kirito K
Immunol Med; 2023 Sep; 46(3):131-142. PubMed ID: 36305377
[TBL] [Abstract][Full Text] [Related]
3. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
4. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.
Kim S; Ruminski P; Singh M; Staser K; Ashami K; Ritchey J; Lim S; DiPersio JF; Choi J
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675621
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.
Huarte E; Peel M; Juvekar A; Dubé P; Sarah S; Stephens L; Stewart B; Long B; Czerniak P; Oliver J; Smith P
Immunotherapy; 2021 Aug; 13(12):977-987. PubMed ID: 34184542
[No Abstract] [Full Text] [Related]
7. Janus Kinase Inhibitors and Cell Therapy.
Assal A; Mapara MY
Front Immunol; 2021; 12():740847. PubMed ID: 34531878
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
De Togni E; Cole O; Abboud R
Front Immunol; 2024; 15():1304065. PubMed ID: 38380328
[TBL] [Abstract][Full Text] [Related]
10. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
Patel AA; Odenike O
Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
[TBL] [Abstract][Full Text] [Related]
11. First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.
De SK
Anticancer Agents Med Chem; 2023; 23(12):1355-1360. PubMed ID: 36959157
[TBL] [Abstract][Full Text] [Related]
12. Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.
Waksal JA; Mascarenhas J
Curr Hematol Malig Rep; 2022 Oct; 17(5):140-154. PubMed ID: 35984598
[TBL] [Abstract][Full Text] [Related]
13. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.
Loscocco GG; Vannucchi AM
Int J Hematol; 2022 May; 115(5):626-644. PubMed ID: 35352288
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
15. Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects.
Mannina D; Kröger N
Drugs; 2019 Sep; 79(14):1499-1509. PubMed ID: 31359326
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
[TBL] [Abstract][Full Text] [Related]
17. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
Spoerl S; Mathew NR; Bscheider M; Schmitt-Graeff A; Chen S; Mueller T; Verbeek M; Fischer J; Otten V; Schmickl M; Maas-Bauer K; Finke J; Peschel C; Duyster J; Poeck H; Zeiser R; von Bubnoff N
Blood; 2014 Jun; 123(24):3832-42. PubMed ID: 24711661
[TBL] [Abstract][Full Text] [Related]
18. Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
Scherber RM; Mesa RA
Blood Rev; 2020 Jul; 42():100716. PubMed ID: 32593470
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
Gupta V; Hari P; Hoffman R
Blood; 2012 Aug; 120(7):1367-79. PubMed ID: 22700718
[TBL] [Abstract][Full Text] [Related]
20. New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib.
Marcuzzi A; Rimondi E; Melloni E; Gonelli A; Grasso AG; Barbi E; Maximova N
Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
